Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved]
Background Hand eczema is a prevalent dermatological condition that significantly impacts the quality of life of affected individuals. Topical corticosteroids, such as Clobetasol Propionate, are commonly employed for management, but concerns regarding long-term use and potential side effects necessi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2024-04-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/13-317/v1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586853276975104 |
|---|---|
| author | Dr Adarshlata Singh Drishti Bhatt |
| author_facet | Dr Adarshlata Singh Drishti Bhatt |
| author_sort | Dr Adarshlata Singh |
| collection | DOAJ |
| description | Background Hand eczema is a prevalent dermatological condition that significantly impacts the quality of life of affected individuals. Topical corticosteroids, such as Clobetasol Propionate, are commonly employed for management, but concerns regarding long-term use and potential side effects necessitate exploration of alternative treatments. This study protocol outlines a randomized controlled trial comparing the efficacy of topical Tofacitinib 2% ointment with Clobetasol Propionate 0.05% ointment in managing hand eczema. Methods The study will be a single-blinded, parallel-group, randomized controlled trial conducted at the Dermatology outpatient department of Acharya Vinoba Bhave Rural Hospital Sawangi Meghe, Wardha, from March 2023 to September 2025. Eligible participants diagnosed with hand eczema will be randomized into two groups: Group 1 will receive Clobetasol Propionate 0.05% ointment, and Group 2 will receive Tofacitinib 2% ointment. The primary outcome measure is the change from baseline in the Hand Eczema Severity Index (HECSI) score, assessed at two weeks and four weeks. Statistical analysis will utilize appropriate parametric and non-parametric tests, with a p-value <0.05 considered significant. Expected Outcome The study is anticipated to provide insights into the comparative efficacy and safety of Tofacitinib and Clobetasol Propionate in managing hand eczema. A favorable outcome for Tofacitinib could suggest its potential as an alternative or adjunctive therapy, offering a more targeted approach with fewer side effects. The findings may contribute to optimized treatment strategies for hand eczema, improving patient outcomes and guiding future research in dermatological therapeutics. |
| format | Article |
| id | doaj-art-47b6ed22dc5c4ac5ac37d8649c412247 |
| institution | Kabale University |
| issn | 2046-1402 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj-art-47b6ed22dc5c4ac5ac37d8649c4122472025-01-25T01:00:01ZengF1000 Research LtdF1000Research2046-14022024-04-0113161953Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved]Dr Adarshlata Singh0Drishti Bhatt1https://orcid.org/0009-0001-8852-0208Dermatology, Venereology and Leprosy, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, IndiaDermatology, Venereology and Leprosy, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, IndiaBackground Hand eczema is a prevalent dermatological condition that significantly impacts the quality of life of affected individuals. Topical corticosteroids, such as Clobetasol Propionate, are commonly employed for management, but concerns regarding long-term use and potential side effects necessitate exploration of alternative treatments. This study protocol outlines a randomized controlled trial comparing the efficacy of topical Tofacitinib 2% ointment with Clobetasol Propionate 0.05% ointment in managing hand eczema. Methods The study will be a single-blinded, parallel-group, randomized controlled trial conducted at the Dermatology outpatient department of Acharya Vinoba Bhave Rural Hospital Sawangi Meghe, Wardha, from March 2023 to September 2025. Eligible participants diagnosed with hand eczema will be randomized into two groups: Group 1 will receive Clobetasol Propionate 0.05% ointment, and Group 2 will receive Tofacitinib 2% ointment. The primary outcome measure is the change from baseline in the Hand Eczema Severity Index (HECSI) score, assessed at two weeks and four weeks. Statistical analysis will utilize appropriate parametric and non-parametric tests, with a p-value <0.05 considered significant. Expected Outcome The study is anticipated to provide insights into the comparative efficacy and safety of Tofacitinib and Clobetasol Propionate in managing hand eczema. A favorable outcome for Tofacitinib could suggest its potential as an alternative or adjunctive therapy, offering a more targeted approach with fewer side effects. The findings may contribute to optimized treatment strategies for hand eczema, improving patient outcomes and guiding future research in dermatological therapeutics.https://f1000research.com/articles/13-317/v1Hand eczema Topical Tofacitinib Clobetasol Propionate Dermatology Randomized controlled trial Hand Eczema Severity Index (HECSI)eng |
| spellingShingle | Dr Adarshlata Singh Drishti Bhatt Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved] F1000Research Hand eczema Topical Tofacitinib Clobetasol Propionate Dermatology Randomized controlled trial Hand Eczema Severity Index (HECSI) eng |
| title | Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved] |
| title_full | Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved] |
| title_fullStr | Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved] |
| title_full_unstemmed | Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved] |
| title_short | Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved] |
| title_sort | comparative study between efficacy of topical tofacitinib 2 ointment versus topical clobetasol propionate 0 05 ointment in hand eczema at a tertiary hospital in central india version 1 peer review 2 approved |
| topic | Hand eczema Topical Tofacitinib Clobetasol Propionate Dermatology Randomized controlled trial Hand Eczema Severity Index (HECSI) eng |
| url | https://f1000research.com/articles/13-317/v1 |
| work_keys_str_mv | AT dradarshlatasingh comparativestudybetweenefficacyoftopicaltofacitinib2ointmentversustopicalclobetasolpropionate005ointmentinhandeczemaatatertiaryhospitalincentralindiaversion1peerreview2approved AT drishtibhatt comparativestudybetweenefficacyoftopicaltofacitinib2ointmentversustopicalclobetasolpropionate005ointmentinhandeczemaatatertiaryhospitalincentralindiaversion1peerreview2approved |